Sign In
Buy CAI
$15.48
-1.04 (-6.30%)
At Close: Jun 03, 2026
Capitan Investment Ltd. Announces Adoption of Semi-Annual Reporting
02:11pm, Thursday, 28'th May 2026
Calgary, Alberta--(Newsfile Corp. - May 28, 2026) - Capitan Investment Ltd. (TSXV: CAI) (the "Corporation") announces that it has elected to adopt semi-annual financial reporting in reliance on the Co
Inaugural story spotlights a woman whose presumed stage 4 metastatic breast cancer diagnosis was corrected by Caris GPSai, an AI-powered tissue-of-origin model, revealing a highly treatable lymphoma I
CAI Advances Multicloud and Secure AI Strategy with AWS and Microsoft
09:02am, Wednesday, 20'th May 2026
ALLENTOWN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- CAI, a global services firm, with more than 40 years of expertise delivering technology solutions to public sector and commercial organizations, announ
Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris
The Caris Lookback Program identified 13,293 patients potentially eligible for newly approved targeted therapies across 10 tumor types IRVING, Texas, May 15, 2026 /PRNewswire/ -- Caris Life Sciences®
Caris Life Sciences Eyes Bigger Oncology Market After IPO as Revenue Jumps 79%
05:06am, Wednesday, 13'th May 2026
Caris Life Sciences NASDAQ: CAI executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following its I
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
03:40pm, Tuesday, 12'th May 2026
Caris Life Sciences, Inc. (CAI) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Targeted gene panels miscalculate tumor mutational burden in 10–15% of patients, directly resulting in incorrect pembrolizumab eligibility determination IRVING, Texas, May 11, 2026 /PRNewswire/ -- C
IRVING, Texas, May 8, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric next-generation AI TechBio company and precision medicine pioneer, today announced that it has
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
10:41am, Friday, 08'th May 2026
Caris Life Sciences, Inc. (CAI) Q1 2026 Earnings Call Transcript
Caris Life Sciences Reports First Quarter 2026 Financial Results
04:05pm, Thursday, 07'th May 2026
Revenue growth of 79% driven by strong performance in molecular profiling services IRVING, Texas, May 7, 2026 /PRNewswire/ -- Caris Life Sciences, Inc. (Nasdaq: CAI), a leading, patient centric, next-
Caris MI Clarity leverages AI to transform how recurrence risk is understood and applied in postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer IRVING, Texa
IRVING, Texas, May 4, 2026 /PRNewswire/ -- Caris Life Sciences ® (NASDAQ: CAI), a leading, patient‑centric, next‑generation AI TechBio company and precision medicine pioneer, today announced that
Capitan Investment Ltd. Announces Appointment of Chief Financial Officer and Chair
12:07pm, Friday, 01'st May 2026
Calgary, Alberta--(Newsfile Corp. - May 1, 2026) - Capitan Investment Ltd. (TSXV: CAI) ("Capitan") announces that effective April 30, 2026, Liqun Hao was appointed the Chief Financial Officer of Capi
Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients
08:30am, Wednesday, 29'th Apr 2026
Caris AI Insights are proprietary and only available to Caris Life Sciences customers IRVING, Texas, April 29, 2026 /PRNewswire/ -- Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, nex
